Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pharmacokinetic and liver metastasis perfusion study of EndoTAG-1
2007-004038-18Phase 2Completed
- Sponsor
- Medigene AG
- Start
- Sep 2007
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EndoTAG-1 in hepatic metastasis and carcinoma, sponsored by Medigene AG. Primary endpoints: Pharmacokinetic profile of EndoTAG-1 and Effect on target liver metastasis perfusion and vascular permeability. Started Sep 2007; status: completed.
02
Drugs
EndoTAG-1
03
Conditions
hepatic metastasiscarcinoma
Beyond the preview
Go deeper on 2007-004038-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004038-18.